{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268815","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.620433+00:00","generated_at":"2026-06-09T00:51:11.725590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera reports Q3 net loss $52.9M; initiates Phase 2 HS trial, receives $40M milestone","bullets":["Net loss of $52.9M in Q3 2023 vs $43.0M loss in Q3 2022; revenue $4.7M down from $9.6M.","First patient dosed in KT-474 (IRAK4) Phase 2 HS trial triggered $40M milestone from Sanofi; Phase 2 AD dosing expected Q4 2023.","KT-333 (STAT3) Phase 1 shows partial response in CTCL patient; Fast Track granted for CTCL/PTCL.","KT-253 (MDM2) achieved proof-of-mechanism; confirmed partial response in Merkel cell carcinoma patient.","KT-413 (IRAKIMiD) development discontinued; cash $435M provides runway into H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268815","json":"https://secwatch.observer/filing/0001193125-23-268815.json","markdown":"https://secwatch.observer/filing/0001193125-23-268815.md","text":"https://secwatch.observer/filing/0001193125-23-268815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/0001193125-23-268815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/d579034d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:51:11.725590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d79c90b2697caea902790114b766e71bf41fff52","claim":"Kymera Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/0001193125-23-268815-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}